NCT05615363View on ClinicalTrials.gov

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

PHASE2CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

October 21, 2024

Study Completion Date

October 21, 2024

Conditions
Cardiac Edema (CHF)
Interventions
DRUG

OPC 131461 10mg group

OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days

DRUG

OPC 131461 5mg group

OPC-131461 5 mg tablet and placebo tablet，once-daily oral administration for 14 days

DRUG

OPC 131461 2mg group

OPC-131461 1 mg tablet x 2，once-daily oral administration for 14 days

DRUG

OPC 131461 1mg group

OPC-131461 1 mg tablet and placebo tablet，once-daily oral administration for 14 days

DRUG

Placebo

Placebo tablet，once-daily oral administration for 14 days

Trial Locations (1)

Unknown

Harasanshin Hospital, Fukuoka

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY